Brief: Biophytis Files With FDA For Authorization To Initiate Sara-31 Phase 3 Study In Sarcopenia
10/07/2023 06:05
July 10 (Reuters) - Biophytis SA ALBPS.PA :
* BIOPHYTIS HAS FILED WITH THE FDA FOR AUTHORIZATION TO
INITIATE
SARA-31 PHASE 3 STUDY IN SARCOPENIA
Source text for Eikon: ID:nEQ7d8TBTa
Further company coverage: ALBPS.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com ; +48 58 769 66 00;))
Recent news on Biophytis SA
See all newsBrief: Biophytis SA Secures $20 Mln For Launch Of Phase 3 Trial In Sarcopenia
Brief: Biophytis Secures Public Funding In Brazil For Obesity Phase 2 Trial
Brief: Biophytis SA Gets EMA Authorization For Phase 2 Clinical Trial In Obesity
Brief: Biophytis Gets EMA & Belgian Regulatory Approval For Phase 3 Sarcopenia Clinical Trial
Brief: Biophytis To Initiate Phase 2 Study In Obesity & Phase 3 Study In Sarcopenia Soon